- $156.05m
- $102.51m
- $42.17m
Brief: Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights
Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Brief: Coherus Oncology Q2 Net Income USD -20.631 Million
Coherus Oncology Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Coherus, Zumutor To Collaborate On ZM008, LOQTORZI Combination Study
Coherus Oncology Q1 sales rise
Coherus Oncology Q4 revenue misses estimates
Brief: Coherus Oncology Q4 Sales USD 12.748 Million Vs. IBES Estimate USD 13.9 Million
U.S. STOCKS ON THE MOVE-Moderna, Mohawk,
U.S. STOCKS ON THE MOVE-Moderna, Mohawk
U.S. STOCKS ON THE MOVE-Opus Genetics, MetaVia, Enbridge
U.S. STOCKS ON THE MOVE-Silver miners, Coherus Oncology, Airbnb
Coherus Oncology tumbles on $50 mln stock sale
Brief: Coherus Oncology Announces Pricing Of Public Offering Of Common Stock
Coherus Oncology tumbles on planned equity offering
Brief: Coherus Oncology Inc - Announces Agreement With Janssen - SEC Filing
Brief: Coherus Oncology Files For Mixed Shelf Offering Of Up To $150 Million- SEC Filing
Coherus Oncology Q3 sales miss estimates, LOQTORZI revenue up 12%